Upcoming conferences

Schedule a meeting with our drug development and manufacturing experts at AAPS & CPhI this November

Regulatory affairs

How do I ensure high-quality regulatory submissions? Quotient is your answer.

Quotient Sciences’ team possesses an in-depth understanding of the evolving clinical trial regulatory environment in Europe and the U.S., ensuring the production of high-quality dossiers and a seamless submission and approval process for your Phase I clinical trial application.

Our highly experienced regulatory specialists and scientists prepare, submit and/or manage:

  • Clinical Trial Authorization (CTA) and Investigational New Drug (IND) applications
  • Institutional Review Board (IRB) / Research Ethics Committee (REC), submissions
  • Administration of Radioactive Substances Advisory Committee (ARSAC) applications for studies requiring dosing of ionizing radiation to human volunteers

Our services also include:

  • Writing and review of Chemistry, Manufacturing and Controls (CMC)  drug substance and drug product sections
  • Writing and reviewing investigator’s brochures (IBs)
  • Advising on quality, preclinical or clinical data requirements to support Phase I clinical trials
  • Providing strategic advice on MHRA, EMA and FDA clinical trial regulatory processes

We have strong collaborative relationships with Institutional Review Board (IRB) / Research Ethics Committees in U.K. and U.S. with combined in-depth and up-to-date understanding of the clinical trial regulatory environment and requirements, which results in high quality submissions and speedy approvals.

Regulatory affairs

Go further with Quotient Sciences

Ready to get started?

Share Your Project Needs With Us

Ask us a question